Breaking News Instant updates and real-time market news.

REGN

Regeneron

$364.32

-1.57 (-0.43%)

, AGN

Allergan

$171.67

-4.18 (-2.38%)

10:10
07/19/18
07/19
10:10
07/19/18
10:10

Regeneron overhang 'effectively lifted' after Allergan data, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond noted that Allergan (AGN) and Molecular Partners disclosed data from two Phase 3 trials comparing the latest DARPin formulation to Lucentis in age-related macular degeneration, calling the data "decidedly a non-starter." While few Regeneron (REGN) investors have expressed concern to Raymond over looming DARPin data, any overhang that did exist due to worries about another potential Eylea competitor in the AMD space have "been effectively lifted" following the DARPin data, said the analyst. He remains a buyer of Regeneron shares and keeps an Overweight rating and $450 price target on the stock.

REGN

Regeneron

$364.32

-1.57 (-0.43%)

AGN

Allergan

$171.67

-4.18 (-2.38%)

  • 19

    Jul

  • 26

    Jul

  • 11

    Aug

  • 20

    Oct

  • 28

    Oct

REGN Regeneron
$364.32

-1.57 (-0.43%)

07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/02/18
RHCO
07/02/18
NO CHANGE
Target $344
RHCO
Hold
Regeneron raised U.S. price of Dupixent by 3%, says SunTrust
Regeneron Pharmaceuticals (REGN) increased the U.S. price of Dupixent by 3.0% from $2,846.16 to $2,941.54 per package, effective June 29, SunTrust analyst Yatin Suneja tells investors in a research note, citing a third-party source. Piper Jaffray also highlighted the 3% price increase. This is the first price increase for Dupixent taken by Regeneron and partner Sanofi (SNY) since the drug was launched in March of 2017, the analyst points out. Suneja believes Dupixent could be on its way to becoming a multi-billion dollar franchise given its "rapid progress" in atopic dermatitis, October FDA action date for asthma and multiple Phase III readouts planned for later this year. The price increase should contribute $14M in incremental sales in 2018, Suneja predicts. The analyst keeps a Hold rating on Regeneron with a $344 price target. This report corrects the launch date of Dupixent.
07/02/18
PIPR
07/02/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron has 'substantial' opportunity for Q2 upside, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that with Dupixent script trends indicated up almost 30% quarter-over-quarter, Regeneron's (REGN) opportunity for Q2 upside is "substantial." Further, Regeneron and Sanofi (SNY) over the weekend raised the list price by 3% for the drug's first ever price increase, Raymond tells investors in a research note. He thinks Dupixent remains well positioned to outperform expectations "this quarter and beyond." The analyst maintains an Overweight rating on Regeneron with a $450 price target.
06/28/18
OPCO
06/28/18
NO CHANGE
Target $410
OPCO
Outperform
Street underestimating Regeneron's cemiplimab potential in CSCC, says Oppenheimer
Oppenheimer analyst Hartaj Singh conducted a survey of 25 high-volume physicians on the product profile for Regeneron's cemiplimab, a breakthrough therapy designated antibody in cutaneous squamous cell carcinoma. The analyst believes the Street has "surprisingly low" expectations for cemiplimab. His survey indicates that CSCC has a large unmet need among relapsed patients following surgical tumor excision, and models $160M in 2019 WW cemiplimab sales, but believes it could be as high as $300-400M due to the high unmet need in this tumor type. Singh reiterates an Outperform rating and $410 price target on the shares.
AGN Allergan
$171.67

-4.18 (-2.38%)

07/12/18
CANT
07/12/18
INITIATION
Target $59
CANT
Overweight
Cantor puts $59 price target on 'undervalued' NASH play Galmed
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Galmed Pharmaceuticals (GLMD) with an Overweight rating and $59 price target. The stock closed yesterday down 45c to $10.55. The company is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fattyacid/bile-acid conjugates, Piros tells investors in a research note. The analyst believes that by Q4 of 2019, only three meaningful non-alcoholic steatohepatitis pivotal programs will be in development: Allergan's (AGN) cenicriviroc, Madrigal Pharmaceuticals' (MDGL) MGL-3196, and Galmed's Aramchol. Of the three drugs, Galmed's has the highest likelihood of achieving improvement on NASH resolution without worsening of fibrosis, and improvement in fibrosis score without worsening of NASH, Piros argues. He believes Galmed is undervalued relative to peers in the NASH space.
07/09/18
MZHO
07/09/18
NO CHANGE
Target $194
MZHO
Neutral
Allergan price target raised to $194 from $176 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Allergan to $194 after extending her model to 2025 to "assess the beneficial impact" of the company's pipeline. Her new price target reflects a long-term outlook but the analyst reiterates a Neutral rating on Allergan.
06/27/18
MAXM
06/27/18
INITIATION
Target $6
MAXM
Buy
VistaGen Therapeutics initiated with a Buy at Maxim
As reported earlier, Maxim analyst Caroline Palomeque initiated VistaGen Therapeutics (VTGN) with a Buy rating and a price target of $6 based on its lead drug candidate, AV-101, an oral antidepressant targeting modulation of the NMDA receptor which is an emerging new class of antidepressants. The analyst notes that while Johnson & Johnson (JNJ) and Allergan (AGN) have first mover advantage in the NMDA class, their respective intranasal and IV in-office administration differentiates AV-101 as an oral at-home alternative. Palomeque notes the company's is progressing with its clinical development, as AV-101 undergoes phase 2 studies in treatment resistant major depressive disorder and adjunctive therapy in frontline failed patients, with data expected in the second half of this year and first half of 2019 respectively.
06/13/18
WELS
06/13/18
NO CHANGE
Target $240
WELS
Outperform
Wells Fargo encouraged by data for Allergan's glaucoma treatment
Wells Fargo analyst David Maris said he was encouraged by the positive topline results reported by Allergan from the first of two Phase 3 studies of its glaucoma treatment Bimatoprost SR, which he believes will eventually strengthen the company's commercial glaucoma franchise. He projects Bimatoprost SR to enter the market in 2020 and grow to sales of $280M in 2022. Maris keeps an Outperform rating on Allergan shares.

TODAY'S FREE FLY STORIES

DWDP

DowDuPont

$32.01

0.99 (3.19%)

15:36
05/21/19
05/21
15:36
05/21/19
15:36
Conference/Events
DowDuPont to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

TOL

Toll Brothers

$38.40

0.88 (2.35%)

15:34
05/21/19
05/21
15:34
05/21/19
15:34
Options
Toll Brothers options imply 8.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

GEO

Geo Group

$22.01

0.18 (0.82%)

15:30
05/21/19
05/21
15:30
05/21/19
15:30
Options
Put spreads in Geo Group as a bearish position is adjusted »

Put spreads in Geo Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$55.88

-7.07 (-11.23%)

, AMZN

Amazon.com

$1,858.97

0.16 (0.01%)

15:26
05/21/19
05/21
15:26
05/21/19
15:26
Recommendations
Kohl's, Amazon.com, Planet Fitness analyst commentary at Jefferies »

Kohl's price target…

KSS

Kohl's

$55.88

-7.07 (-11.23%)

AMZN

Amazon.com

$1,858.97

0.16 (0.01%)

PLNT

Planet Fitness

$76.76

-1.01 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 03

    Jun

  • 06

    Jun

  • 24

    Jun

TSLA

Tesla

$205.05

-0.2 (-0.10%)

15:24
05/21/19
05/21
15:24
05/21/19
15:24
Periodicals
Tesla lowers base price of new Model S, Model X cars, Electrek reports »

Tesla cut the base price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

URBN

Urban Outfitters

$27.07

0.11 (0.41%)

15:19
05/21/19
05/21
15:19
05/21/19
15:19
Options
Urban Outfitters options imply 13.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 04

    Jun

WYNN

Wynn Resorts

$120.62

1.5 (1.26%)

15:17
05/21/19
05/21
15:17
05/21/19
15:17
Recommendations
Wynn Resorts analyst commentary  »

Wynn Resorts named as new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
05/21/19
05/21
15:17
05/21/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCX

OncoCyte

$5.08

-0.08 (-1.55%)

15:16
05/21/19
05/21
15:16
05/21/19
15:16
Hot Stocks
OncoCyte presents 'positive' results from R&D validation study of DetermaVu »

OncoCyte presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
05/21/19
05/21
15:16
05/21/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YPF

YPF

$15.35

(0.00%)

15:15
05/21/19
05/21
15:15
05/21/19
15:15
Options
YPF put volume heavy and directionally bearish »

Bearish flow noted in YPF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:10
05/21/19
05/21
15:10
05/21/19
15:10
General news
Treasury Market Summary »

Treasury Market Summary:…

JWN

Nordstrom

$37.82

0.36 (0.96%)

15:04
05/21/19
05/21
15:04
05/21/19
15:04
Options
Nordstrom options imply 11.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

EADSY

Airbus

$0.00

(0.00%)

15:03
05/21/19
05/21
15:03
05/21/19
15:03
Periodicals
Airbus CEO hints at launch of new A321 plane, Reuters says »

Airbus CEO Guillaume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPL

Texas Pacific Land Trust

$853.39

8.39 (0.99%)

15:02
05/21/19
05/21
15:02
05/21/19
15:02
Hot Stocks
Texas Pacific Land Trust files lawsuit against trustee Eric Oliver »

Texas Pacific Land Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$111.18

1.94 (1.78%)

15:00
05/21/19
05/21
15:00
05/21/19
15:00
Options
Lowe's options volume is 3X daily average ahead of earnings »

Lowe's options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 31

    May

MNK

Mallinckrodt

$9.55

-3.47 (-26.65%)

14:59
05/21/19
05/21
14:59
05/21/19
14:59
Recommendations
Mallinckrodt analyst commentary at Raymond James »

Mallinckrodt could lose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.97

-0.26 (-0.30%)

14:58
05/21/19
05/21
14:58
05/21/19
14:58
Hot Stocks
Philip Morris announces creation of new senior management team roles »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$25.41

-0.39 (-1.51%)

14:49
05/21/19
05/21
14:49
05/21/19
14:49
Options
Sea Limited options imply 14.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AAPL

Apple

$187.49

4.43 (2.42%)

14:31
05/21/19
05/21
14:31
05/21/19
14:31
Periodicals
Apple expands keyboard repair program to include butterfly mechanism, Verge says »

Apple is updating its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

CC

Chemours

$23.77

1.35 (6.02%)

14:30
05/21/19
05/21
14:30
05/21/19
14:30
Options
5K Chemours Oct 16 - 20 put spreads bought for 92c as shares rally »

5K Chemours Oct 16 - 20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
05/21/19
05/21
14:25
05/21/19
14:25
Conference/Events
Cowen biotechnology analysts to hold an analyst/industry conference call »

Biotechnology Analysts…

QRVO

Qorvo

$62.14

0.84 (1.37%)

14:22
05/21/19
05/21
14:22
05/21/19
14:22
Recommendations
Qorvo analyst commentary at Oppenheimer »

Qorvo could be first to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PED

PEDEVCO Corp.

$2.02

-0.06 (-2.88%)

14:21
05/21/19
05/21
14:21
05/21/19
14:21
Hot Stocks
PEDEVCO Corp. announces sale of stock to SK Energy, two unaffiliated investors »

PEDEVCO Corp. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PED

PEDEVCO Corp.

$2.02

-0.06 (-2.88%)

14:20
05/21/19
05/21
14:20
05/21/19
14:20
Hot Stocks
Breaking Hot Stocks news story on PEDEVCO Corp. »

PEDEVCO Corp. trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.